YLM-32423-01880
4 vaccinations
5 coded responses
33 check-ins
5 free-text entries
0 call cases
- Sex
- Male
- Age at first dose
- 66+
- ZIP prefix
- 024 / MA
- Registered
- 2021-03-04
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-04
Registered in v-safe
-
2021-03-04
Dose 1 — Pfizer-BioNTech
- 2021-03-04
- 2021-03-05
- 2021-03-06
- 2021-03-07
- 2021-03-09
- 2021-03-10
- 2021-03-11
- 2021-03-18
- 2021-03-25
-
2021-03-26
Dose 2 — Pfizer-BioNTech
- 2021-03-26
-
2021-03-27
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain · Chills, Headache, Muscle or body achesAdult check-in
- 2021-03-28
- 2021-03-29
- 2021-03-30
- 2021-03-31
- 2021-04-01
- 2021-04-02
- 2021-04-09
- 2021-04-16
- 2021-04-23
-
2021-04-30
Survey response — day 35, dose 2MedDRA: Exercise tolerance decreased, Injection site pain — Feeling: GoodFree text: Reemergence of pain at the injection site, notably after activities of intensive or repetitive muscle use. Goes away after a period of rest.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-05-07
-
2021-06-25
Survey response — 3 months, dose 2MedDRA: Injection site pain — Feeling: GoodFree text: Lingering soreness at injection site. Last covid Pfizer vaccination was 3/26/2021.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-09-24
Survey response — 6 months, dose 2MedDRA: Basal cell carcinoma, Squamous cell carcinoma — Feeling: GoodFree text: One Squamous Cell Carcinoma and one Basal Cell Carcinoma to be surgically removed this fall.MedDRA releases: 2024-11 · check-in free text available
-
2021-10-14
Dose 3 — Pfizer-BioNTech
-
2022-03-26
Survey response — 12 months, dose 2MedDRA: Neuritis, Neurological symptom, Office visit — Feeling: GoodFree text: Neuritis/carpal tunnel syndrome symptoms. Treatment by PCP doctor.MedDRA releases: 2024-11 · check-in free text available
-
2022-04-15
Dose 4 — Pfizer-BioNTech
- 2022-04-24
- 2022-04-29
- 2022-05-06
- 2022-05-13
-
2022-05-20
Survey response — day 35, dose 4MedDRA: Diarrhoea — Feeling: GoodFree text: Diarrhea for 5 days; cleared up 4 days agoMedDRA releases: 2024-11 · check-in free text available
- 2022-05-27
- 2022-07-15
- 2022-10-14
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-04 | Pfizer-BioNTech | |
| 2 | 2021-03-26 | Pfizer-BioNTech | |
| 3 | 2021-10-14 | Pfizer-BioNTech | No |
| 4 | 2022-04-15 | Pfizer-BioNTech | No |
Free text
Release 8 — day 35, dose 2
Symptoms: Reemergence of pain at the injection site, notably after activities of intensive or repetitive muscle use. Goes away after a period of rest.
Release 9 — 3 months, dose 2
Symptoms: Lingering soreness at injection site. Last covid Pfizer vaccination was 3/26/2021.
Release 9 — 6 months, dose 2
Symptoms: One Squamous Cell Carcinoma and one Basal Cell Carcinoma to be surgically removed this fall.
Release 11 — 12 months, dose 2
Symptoms: Neuritis/carpal tunnel syndrome symptoms. Treatment by PCP doctor.
Release 11 — day 35, dose 4
Symptoms: Diarrhea for 5 days; cleared up 4 days ago
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Basal cell carcinoma | · | · | ✓ |
| SD | Diarrhoea | · | · | ✓ |
| SD | Exercise tolerance decreased | ✓ | ✓ | ✓ |
| SD | Injection site pain | ✓ | ✓ | ✓ |
| SD | Neuritis | · | · | ✓ |
| SD | Neurological symptom | · | · | ✓ |
| SD | Office visit | · | · | ✓ |
| SD | Squamous cell carcinoma | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release